These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 23084583)

  • 1. In situ analysis of HER2 mRNA in gastric carcinoma: comparison with fluorescence in situ hybridization, dual-color silver in situ hybridization, and immunohistochemistry.
    Kim MA; Jung JE; Lee HE; Yang HK; Kim WH
    Hum Pathol; 2013 Apr; 44(4):487-94. PubMed ID: 23084583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
    Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
    Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
    Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
    Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
    Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.
    Yano T; Doi T; Ohtsu A; Boku N; Hashizume K; Nakanishi M; Ochiai A
    Oncol Rep; 2006 Jan; 15(1):65-71. PubMed ID: 16328035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
    Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
    Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
    Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
    J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas.
    Cho EY; Srivastava A; Park K; Kim J; Lee MH; Do I; Lee J; Kim KM; Sohn TS; Kang WK; Kim S
    Pathology; 2012 Apr; 44(3):216-20. PubMed ID: 22437741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK; Tjan S; Parkes RK; O'Malley FP
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages.
    Cho J; Jeong J; Sung J; Sung CO; Kim KM; Park CK; Choi MG; Sohn TS; Bae JM; Kim S
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S477-84. PubMed ID: 23274580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early HER2 dysregulation in gastric and oesophageal carcinogenesis.
    Fassan M; Mastracci L; Grillo F; Zagonel V; Bruno S; Battaglia G; Pitto F; Nitti D; Celiento T; Zaninotto G; Fiocca R; Rugge M
    Histopathology; 2012 Nov; 61(5):769-76. PubMed ID: 22882541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study.
    Loussouarn D; Brunon J; Avet-Loiseau H; Campone M; Mosnier JF
    Hum Pathol; 2006 Apr; 37(4):415-21. PubMed ID: 16564915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
    Hechtman JF; Polydorides AD
    Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of HER2 immunohistochemical results using a monoclonal antibody (SV2-61γ) and a polyclonal antibody (for Dako HercepTest) in advanced gastric cancer.
    Tamura G; Osakabe M; Yanagawa N; Ogata SY; Nomura T; Fukushima N; Ito Y; Tabuchi M
    Pathol Int; 2012 Aug; 62(8):513-7. PubMed ID: 22827758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of HER2 overexpression and amplification in small intestinal adenocarcinoma.
    Chan OT; Chen ZM; Chung F; Kawachi K; Phan DC; Himmelfarb E; Lin F; Perry A; Wang HL
    Am J Clin Pathol; 2010 Dec; 134(6):880-5. PubMed ID: 21088150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dual-color silver-enhanced in-situ hybridization for determination of HER2 gene amplification in gastric carcinoma].
    Fan D; Li Y; Ran W; Yu W; Li H
    Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):4-7. PubMed ID: 24713241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression profiling of breast tumors based on human epidermal growth factor receptor 2 status defines migration-related genes.
    Cuadros M; Cano C; López FJ; López-Castro R; Concha A
    Pathobiology; 2013; 80(1):32-40. PubMed ID: 22832278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization.
    Im SA; Kim JW; Kim JS; Kim MA; Jordan B; Pickl M; Han SW; Oh DY; Lee HJ; Kim TY; Kim WH; Yang HK; Bang YJ
    Diagn Mol Pathol; 2011 Jun; 20(2):94-100. PubMed ID: 21532492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis.
    Fassan M; Pizzi M; Realdon S; Balistreri M; Guzzardo V; Zagonel V; Castoro C; Mastracci L; Farinati F; Nitti D; Zaninotto G; Rugge M
    Hum Pathol; 2013 Sep; 44(9):1804-10. PubMed ID: 23618359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.